Literature DB >> 8576306

Monoclonal antibody blocking tests for the detection of HSV-1- and HSV-2-specific humoral responses: comparison with western blot assay.

M J Slomka1, R L Ashley, F M Cowan, A Cross, D W Brown.   

Abstract

Monoclonal antibody blocking radioimmunoassays (MAb block RIAs) which detect specific humoral responses to each of the two human herpes simplex virus (HSV) types are described. RIAs were compared with Western blot assay (WBA) in a blind study of 64 sera obtained from clinically well-documented cases of genital herpes. WBA and MAb block RIA each detected HSV-1 antibodies in 16/17 (94%) sera from confirmed HSV-1 genital infections (first episodes and recurrent infections). Detection of HSV-2 antibody in 21 sera from HSV-2 first episodes was more effective by WBA which identified homologous antibody in 19 (96%), whereas MAb block RIA detected HSV-2 antibody in 16 (76%). HSV-2 antibody was detected in 24/25 (96%) sera from recurrent HSV-2 infections by WBA and by MAb block RIA, the highest degree of concordance for both methods. In addition, the MAb block RIA may be more effective in detecting the presence of HSV-1 antibody in sera from recurrent HSV-2 cases. Prevalence of HSV-1 and HSV-2 antibody was measured by the MAb block RIAs in 3 UK human study populations which consisted of 100 children/young adolescents, 104 adult blood donors and 80 genito-urinary medicine clinic attenders.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8576306     DOI: 10.1016/0166-0934(95)00042-s

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  17 in total

1.  Novel approach for specific detection of herpes simplex virus type 1 and 2 antibodies and immunoglobulin G and M antibodies.

Authors:  B Ohana; M Lipson; N Vered; I Srugo; M Ahdut; A Morag
Journal:  Clin Diagn Lab Immunol       Date:  2000-11

Review 2.  Sorting out the new HSV type specific antibody tests.

Authors:  R L Ashley
Journal:  Sex Transm Infect       Date:  2001-08       Impact factor: 3.519

3.  Genital herpes, "the new paradigm".

Authors:  S Taylor; S Drake; D Pillay
Journal:  J Clin Pathol       Date:  1999-01       Impact factor: 3.411

4.  Evaluation of the HerpeSelect Express rapid test in the detection of herpes simplex virus type 2 antibodies in patients with genital ulcer disease.

Authors:  Hani Al-Shobaili; Khaled M Hassanein; Marwa Salah Mostafa; Ali Saleh Al Duways
Journal:  J Clin Lab Anal       Date:  2014-03-28       Impact factor: 2.352

5.  Performance of the HerpeSelect (Focus) and Kalon enzyme-linked immunosorbent assays for detection of antibodies against herpes simplex virus type 2 by use of monoclonal antibody-blocking enzyme immunoassay and clinicovirological reference standards in Brazil.

Authors:  Maria Claudia Nascimento; Suzete Ferreira; Ester Sabino; Ingrid Hamilton; John Parry; Claudio S Pannuti; Philippe Mayaud
Journal:  J Clin Microbiol       Date:  2007-05-16       Impact factor: 5.948

6.  HSV type specific antibody tests: patients are ready, are clinicians?

Authors:  R L Ashley; L Corey
Journal:  Genitourin Med       Date:  1997-08

7.  Increased ISGylation in Cases of TBI-Exposed ALS Veterans.

Authors:  Joshua Schwartzenburg; Meredith Juncker; Ryan Reed; Shyamal Desai
Journal:  J Neuropathol Exp Neurol       Date:  2019-03-01       Impact factor: 3.685

8.  Genital herpes serotesting: a study of the epidemiology and patients' knowledge and attitude among STD clinic attenders in Coventry, UK.

Authors:  N Narouz; P S Allan; A H Wade; S Wagstaffe
Journal:  Sex Transm Infect       Date:  2003-02       Impact factor: 3.519

Review 9.  Genital herpes: review of the epidemic and potential use of type-specific serology.

Authors:  R L Ashley; A Wald
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

10.  Role of type specific herpes simplex virus serology in the diagnosis and management of genital herpes.

Authors:  P E Munday; J Vuddamalay; M J Slomka; D W Brown
Journal:  Sex Transm Infect       Date:  1998-06       Impact factor: 3.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.